51
|
Vinuesa T, Herráez R, Oliver L, Elizondo E, Acarregui A, Esquisabel A, Pedraz JL, Ventosa N, Veciana J, Viñas M. Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease. Am J Trop Med Hyg 2017; 97:1469-1476. [PMID: 29016287 DOI: 10.4269/ajtmh.17-0044] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
This article describes the characterization of various encapsulated formulations of benznidazole, the current first-line drug for the treatment of Chagas disease. Given the adverse effects of benznidazole, safer formulations of this drug have a great interest. In fact, treatment of Chagas disease with benznidazole has to be discontinued in as much as 20% of cases due to side effects. Furthermore, modification of delivery and formulations could have potential effects on the emergence of drug resistance. The trypanocidal activity of new nanostructured formulations of benznidazole to eliminate Trypanosoma cruzi was studied in vitro as well as their toxicity in two cultured mammalian cell lines (HepG2 and Fibroblasts). Nanoparticles tested included nanostructured lipid carriers, solid lipid nanoparticles, liposomes, quatsomes, and cyclodextrins. The in vitro cytotoxicity of cyclodextrins-benznidazole complexes was significantly lower than that of free benznidazole, whereas their trypanocidal activity was not hampered. These results suggest that nanostructured particles may offer improved therapeutics for Chagas disease.
Collapse
Affiliation(s)
- Teresa Vinuesa
- Department of Pathology and Experimental Therapeutics, Medical School, University of Barcelona, Barcelona, Spain
| | - Rocio Herráez
- Department of Pathology and Experimental Therapeutics, Medical School, University of Barcelona, Barcelona, Spain
| | - Laura Oliver
- Department of Pathology and Experimental Therapeutics, Medical School, University of Barcelona, Barcelona, Spain
| | - Elisa Elizondo
- Ciber-BBN (Nanomol), Department of Molecular Nanoscience and Organic Materials, Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Cerdanyola del Vallès, Spain
| | - Argia Acarregui
- Ciber-BBN (NanoBioCel), Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Spain
| | - Amaia Esquisabel
- Ciber-BBN (NanoBioCel), Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Spain
| | - Jose Luis Pedraz
- Ciber-BBN (NanoBioCel), Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Spain
| | - Nora Ventosa
- Ciber-BBN (Nanomol), Department of Molecular Nanoscience and Organic Materials, Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Cerdanyola del Vallès, Spain
| | - Jaume Veciana
- Ciber-BBN (Nanomol), Department of Molecular Nanoscience and Organic Materials, Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Cerdanyola del Vallès, Spain
| | - Miguel Viñas
- Department of Pathology and Experimental Therapeutics, Medical School, University of Barcelona, Barcelona, Spain
| |
Collapse
|
52
|
Altube MJ, Cutro A, Bakas L, Morilla MJ, Disalvo EA, Romero EL. Nebulizing novel multifunctional nanovesicles: the impact of macrophage-targeted-pH-sensitive archaeosomes on a pulmonary surfactant. J Mater Chem B 2017; 5:8083-8095. [PMID: 32264647 DOI: 10.1039/c7tb01694h] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
In this study, a NE-U22 vibrating mesh Omron nebulizer was used to deliver the Lissamine™ rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt (Rh-PE) and 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS)/p-xylene-bis-pyridinium bromide (DPX) double-labelled macrophage-targeted pH-sensitive archaeosomes (ApH, 174 ± 48 nm, -30 ± 13 mV unilamellar nanovesicles made of dioleoyl-sn-glycero-3-phosphoethanolamine: [total polar archaeolipids from the hyperhalophile archaebacteria Halorubrum tebenquichense]: cholesteryl hemisuccinate 4.2 : 2.8 : 3 w : w : w) to J774A.1 cells covered by a Prosurf pulmonary surfactant (PS) monolayer at or below the equilibrium surface pressure πe. The uptake and cytoplasmic drug release from ApH were assessed by flow cytometry of Rh-PE and HPTS fluorescence, respectively. Despite being soft matter, nanovesicles are submitted to the dismantling interactions of shear stress of nebulization and contact with the surfactant barrier, and at least a fraction of nebulized ApH was found to be stable enough to execute higher cytoplasmic delivery than archaeolipid-lacking vesicles. Nebulized ApH increased the PS tensioactivity to just below πe, which was beyond the physiological range; this finding indicated that changes in lung surfactant function induced by nebulized nanovesicles were less likely to occur in vivo. The cytoplasmic delivery from ApH slightly decreased across monolayers at πe; this suggested that nanovesicles crossed the PS in a fashion inversely related to monolayer compression. Laurdan generalized polarization and fluorescence anisotropy were used to reveal that nanovesicles neither depleted B and C proteins of the PS nor increased the fluidity of the PS. Together with the feasibility of the cytoplasmic drug delivery upon nebulization, our results suggest that ApH are structurally unique nanovesicles that would not induce biophysical changes leading to PS inactivation and open the door to deeper future translational studies.
Collapse
Affiliation(s)
- Maria Julia Altube
- Nanomedicine Research Program-2, Science and Technology Department, National University of Quilmes, Bernal, Buenos Aires, Argentina.
| | | | | | | | | | | |
Collapse
|
53
|
Sans-Serramitjana E, Jorba M, Pedraz JL, Vinuesa T, Viñas M. Determination of the spatiotemporal dependence of Pseudomonas aeruginosa biofilm viability after treatment with NLC-colistin. Int J Nanomedicine 2017; 12:4409-4413. [PMID: 28652741 PMCID: PMC5476584 DOI: 10.2147/ijn.s138763] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
The emergence of colistin-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients, particularly after long-term inhalation treatments, has been recently reported. Nanoen-capsulation may enable preparations to overcome the limitations of conventional pharmaceutical forms. We have determined the time-dependent viability of P. aeruginosa biofilms treated with both free and nanoencapsulated colistin. We also examined the relationship between the optimal anti-biofilm activity of nanostructured lipid carrier (NLC)-colistin and the structural organization of the biofilm itself. The results showed the more rapid killing of P. aeruginosa bacterial biofilms by NLC-colistin than by free colistin. However, the two formulations did not differ in terms of the final percentages of living and dead cells, which were higher in the inner than in the outer layers of the treated biofilms. The effective anti-biofilm activity of NLC-colistin and its faster killing effect recommend further studies of its use over free colistin in the treatment of P. aeruginosa infections in CF patients.
Collapse
Affiliation(s)
- Eulalia Sans-Serramitjana
- Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona
| | - Marta Jorba
- Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona
| | - José Luis Pedraz
- Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Vitoria, Spain
| | - Teresa Vinuesa
- Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona
| | - Miguel Viñas
- Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona
| |
Collapse
|
54
|
ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. J Control Release 2017; 249:103-110. [DOI: 10.1016/j.jconrel.2017.01.039] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 01/25/2017] [Accepted: 01/27/2017] [Indexed: 11/20/2022]
|
55
|
Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med 2017; 124:6-14. [PMID: 28284323 DOI: 10.1016/j.rmed.2017.01.006] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 01/12/2017] [Accepted: 01/23/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Inhaled medication is the cornerstone of the pharmacological treatment for patients with asthma and chronic obstructive pulmonary disease (COPD). Several inhaler devices exist, and each device has specific characteristics to achieve the optimal inhalation of drugs. The correct use of inhaler devices is not granted and patients may incur in mistakes when using pressurized metered-dose inhalers (pMDIs) or dry-powder inhaler (DPIs). The incorrect use of inhaler devices can lead to a poorly controlled disease status. Unfortunately, guidelines provide limited guidance regarding the choice of devices. This article presents a review of the literature on different inhaler device requirements. Data from literature (PubMed and Google Scholar) on the commercially available inhaler devices have been evaluated and the history of inhaler medicine described. Furthermore, advantages and disadvantages of each type of device have been analyzed. The evaluation of literature indicated the availability of robust data on the devices characteristics and factors influencing selection of delivery devices. Each type of device has its own pro and cons. The age, cognitive status, visual acuity, manual dexterity, manual strength and ability to coordinate the inhaler actuation with inhalation may be as important as the disease severity in determining the correct approach to delivery of respiratory medication. The administration of effective therapies via a device that is simple to use and accepted by patients may help to improve treatment outcomes in patients with COPD.
Collapse
Affiliation(s)
- Paola Rogliani
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy.
| | - Luigino Calzetta
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy
| | - Angelo Coppola
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy
| | - Francesco Cavalli
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy
| | - Josuel Ora
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy
| | - Ermanno Puxeddu
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy
| | - Maria Gabriella Matera
- Second University of Naples, Department of Experimental Medicine, Unit of Pharmacology, Naples, Italy
| | - Mario Cazzola
- University of Rome Tor Vergata, Department of Systems Medicine, Rome, Italy
| |
Collapse
|
56
|
Wang Y, Zhu L, Wang Y, Li L, Lu Y, Shen L, Zhang LW. Ultrasensitive GSH-Responsive Ditelluride-Containing Poly(ether-urethane) Nanoparticles for Controlled Drug Release. ACS APPLIED MATERIALS & INTERFACES 2016; 8:35106-35113. [PMID: 27966861 DOI: 10.1021/acsami.6b14639] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
A novel ultrasensitive redox-responsive system for the controlled release of doxorubicin (DOX) was fabricated by ditelluride-containing poly(ether-urethane) copolymers. In this study, the ditelluride group was introduced for the first time into water-soluble copolymers used for drug delivery. Doxorubicin loaded in the copolymer nanoparticles can be released in a controlled manner through the cleavage of ditelluride bonds by glutathione (GSH). The ditelluride-containing poly(ether-urethane) nanoparticles were demonstrated to be biocompatible as drug delivery vehicles, therefore opening a new avenue in drug delivery systems for chemotherapy. Furthermore, the in vitro and in vivo studies revealed that the DOX-loaded ditelluride-containing poly(ether-urethane) nanoparticles exhibited efficient uptake in cancer cells, specific tumor targeting and antitumor activity, indicating their excellent potential as novel nanocarriers for drug delivery and cancer therapy.
Collapse
Affiliation(s)
- Yangyun Wang
- School for Radiological & Interdisciplinary sciences (RAD-X) and School of Radiation Medicine and Protection, Soochow University , Suzhou, 215123 Jiangsu, China
- Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions , 199 Renai Road, Suzhou Industrial Park, Suzhou, 215123 Jiangsu, China
| | - Lina Zhu
- The Second Affiliated Hospital of Soochow University , 1055 Sanxiang Road, Suzhou, 215004 Jiangsu, China
| | - Yong Wang
- School for Radiological & Interdisciplinary sciences (RAD-X) and School of Radiation Medicine and Protection, Soochow University , Suzhou, 215123 Jiangsu, China
- Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions , 199 Renai Road, Suzhou Industrial Park, Suzhou, 215123 Jiangsu, China
| | - Liubing Li
- The Second Affiliated Hospital of Soochow University , 1055 Sanxiang Road, Suzhou, 215004 Jiangsu, China
| | - Yufeng Lu
- The Second Affiliated Hospital of Soochow University , 1055 Sanxiang Road, Suzhou, 215004 Jiangsu, China
| | - Liqin Shen
- The Second Affiliated Hospital of Soochow University , 1055 Sanxiang Road, Suzhou, 215004 Jiangsu, China
| | - Leshuai W Zhang
- School for Radiological & Interdisciplinary sciences (RAD-X) and School of Radiation Medicine and Protection, Soochow University , Suzhou, 215123 Jiangsu, China
- Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions , 199 Renai Road, Suzhou Industrial Park, Suzhou, 215123 Jiangsu, China
| |
Collapse
|
57
|
Xie L, Song X, Guo W, Wang X, Wei L, Li Y, Lv L, Wang W, Chen TC, Song X. Therapeutic effect of TMZ-POH on human nasopharyngeal carcinoma depends on reactive oxygen species accumulation. Oncotarget 2016; 7:1651-62. [PMID: 26625208 PMCID: PMC4811487 DOI: 10.18632/oncotarget.6410] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Accepted: 11/20/2015] [Indexed: 12/17/2022] Open
Abstract
Nasopharyngeal carcinoma (NPC) is a common head and neck malignancy without efficient chemotherapeutic agents for it. In our current study, we demonstrated the cytotoxicity effects of a newly patented compound temozolomide–perillyl alcohol (TMZ-POH) on NPC in vitro and in vivo, and the possible mechanisms involved. Human NPC cell lines CNE1, CNE2, HNE2, and SUME-α were treated with control (DMSO), TMZ, POH, TMZ plus POH, and TMZ-POH. Our data indicated that TMZ-POH could inhibit NPC cell proliferation, cause G2/M arrest and DNA damage. TMZ-POH triggered apoptosis in NPC cells via significant activation of caspase-3 and poly(ADP-ribose) polymerase (PARP). Importantly, TMZ-POH-induced cell death was found to be associated with (i) the loss of inner mitochondrial membrane potential (ΔΨm) and release of mitochondrial Cytochrome c, (ii) the increase in ROS generation, and (iii) the activation of stress-activated protein kinases (SAPK)/c-Jun N-terminal kinases (JNK) signaling pathway. The generation of ROS in response to TMZ-POH seems to play a crucial role in the cell death process since the blockage of ROS production using the antioxidant N-acetyl-L-cysteine or catalase reversed the TMZ-POH-induced JNK activation, DNA damage, and cancer cell apoptosis. These results provide the rationale for further research and preclinical investigation of the antitumor effect of TMZ-POH against human NPC.
Collapse
Affiliation(s)
- Li Xie
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Xingguo Song
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Wei Guo
- Ultrasound Diagnosis Department, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Xingwu Wang
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Ling Wei
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Yang Li
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Liyan Lv
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| | - Weijun Wang
- Department of Neurological Surgery and Pathology, University of Southern California, Los Angeles, CA, United States of America
| | - Thomas C Chen
- Department of Neurological Surgery and Pathology, University of Southern California, Los Angeles, CA, United States of America
| | - Xianrang Song
- Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, China
| |
Collapse
|
58
|
Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in vivo evaluation. Int J Pharm 2016; 516:364-371. [PMID: 27884712 DOI: 10.1016/j.ijpharm.2016.11.046] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 10/26/2016] [Accepted: 11/20/2016] [Indexed: 11/20/2022]
Abstract
The objective of this study was to prepare solid lipid nanoparticles (SLNs) for sustained pulmonary delivery of Yuxingcao essential oil (YEO). Three YEO loaded SLNs (SLN-200, SLN-400 and SLN-800) with different particle size were prepared and separated following a high-shear homogenization technique using Compritol 888 ATO as lipid and polyvinyl alcohol as an emulsifier. The particle size, zeta potential, drug encapsulation efficiency and drug loading of the SLNs were determined to be between 171 and 812nm, -17.1 and -19.3mV, between 76.6 and 90.2% and between 2.34 and 3.12%, respectively whereas the in vitro release data showed that the SLNs led to sustained drug release up to 48h. In addition, the SLN suspensions after nebulization conferred the fine particle fractions (<5.4μm) of 67.4-75.8%. Following intratracheal administration to rats, YEO loaded SLNs not only prolonged pulmonary retention up to 24h, but also increased AUC values (15.4, 18.2 and 26.3μg/gh for SLN-200, SLN-400 and SLN-800, respectively) by 4.5-7.7 folds compared to the intratracheally dosed YEO solution and by 257-438 folds to the intravenously dosed YEO solution, respectively. The present results were the first to show that YEO loaded SLNs may sustain YEO inhalation delivery and improve local bioavailability, representing a promising inhalable carrier to attain once daily application.
Collapse
|
59
|
Kakhi Z, Frisch B, Heurtault B, Pons F. Liposomal constructs for antitumoral vaccination by the nasal route. Biochimie 2016; 130:14-22. [DOI: 10.1016/j.biochi.2016.07.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 07/06/2016] [Indexed: 11/27/2022]
|
60
|
Zhang Y, Li Z, Zhang K, Yang G, Wang Z, Zhao J, Hu R, Feng N. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans -ferulic acid ascompared with conventional solid lipid nanoparticles. Int J Pharm 2016; 511:57-64. [DOI: 10.1016/j.ijpharm.2016.06.131] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 06/13/2016] [Accepted: 06/29/2016] [Indexed: 02/08/2023]
|
61
|
Sans-Serramitjana E, Fusté E, Martínez-Garriga B, Merlos A, Pastor M, Pedraz J, Esquisabel A, Bachiller D, Vinuesa T, Viñas M. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J Cyst Fibros 2016; 15:611-8. [DOI: 10.1016/j.jcf.2015.12.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Revised: 11/18/2015] [Accepted: 12/02/2015] [Indexed: 01/13/2023]
|
62
|
Cipolla D. Will pulmonary drug delivery for systemic application ever fulfill its rich promise? Expert Opin Drug Deliv 2016; 13:1337-40. [DOI: 10.1080/17425247.2016.1218466] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
63
|
Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug. Pharm Res 2016; 33:2748-62. [PMID: 27439506 PMCID: PMC5040743 DOI: 10.1007/s11095-016-2002-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Accepted: 07/13/2016] [Indexed: 02/07/2023]
Abstract
Purpose In order to attenuate the drug release rate, a single freeze-thaw step was previously shown to convert encapsulated drug into a single nanocrystal within each liposome vesicle. The goal of this study was to alter the nanocrystalline character, and thus the drug encapsulation state and release profile, by addition of surfactant prior to freeze-thaw. Methods A liposomal ciprofloxacin (CFI) formulation was modified by the addition of surfactant and frozen. After thawing, these formulations were characterized in terms of drug encapsulation by centrifugation-filtration, liposome structure by cryo-TEM imaging, vesicle size by dynamic light scattering, and in vitro release (IVR) performance. Results The addition of increasing levels of polysorbate 20 (0.05 to 0.4%) or Brij 30 (0.05 to 0.3%) to the CFI preparations followed by subsequent freeze-thaw, resulted in a greater proportion of vesicles without drug nanocrystals and reduced the extent of growth of the nanocrystals thus leading to modified release rates including an increase in the ratio of non-encapsulated to sustained release of drug. Conclusions This study provides another lever to achieve the desired release rate profile from a liposomal formulation by addition of surfactant and subsequent freeze-thaw, and thus may provide a personalized approach to treating patients.
Collapse
|
64
|
Dolinina ES, Parfenyuk EV. Development of Novel Delivery System for Cardiovascular Drug Molsidomine: Influence of Synthesis Method and Conditions on Molsidomine Release From Its Composites With Hydrophilic Silica In Vitro. J Pharm Sci 2016; 105:1952-1959. [DOI: 10.1016/j.xphs.2016.03.042] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 03/24/2016] [Accepted: 03/30/2016] [Indexed: 10/21/2022]
|
65
|
Current Trends in Development of Liposomes for Targeting Bacterial Biofilms. Pharmaceutics 2016; 8:pharmaceutics8020018. [PMID: 27231933 PMCID: PMC4932481 DOI: 10.3390/pharmaceutics8020018] [Citation(s) in RCA: 105] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 05/17/2016] [Accepted: 05/18/2016] [Indexed: 12/26/2022] Open
Abstract
Biofilm targeting represents a great challenge for effective antimicrobial therapy. Increased biofilm resistance, even with the elevated concentrations of very potent antimicrobial agents, often leads to failed therapeutic outcome. Application of biocompatible nanomicrobials, particularly liposomally-associated nanomicrobials, presents a promising approach for improved drug delivery to bacterial cells and biofilms. Versatile manipulations of liposomal physicochemical properties, such as the bilayer composition, membrane fluidity, size, surface charge and coating, enable development of liposomes with desired pharmacokinetic and pharmacodynamic profiles. This review attempts to provide an unbiased overview of investigations of liposomes destined to treat bacterial biofilms. Different strategies including the recent advancements in liposomal design aiming at eradication of existing biofilms and prevention of biofilm formation, as well as respective limitations, are discussed in more details.
Collapse
|
66
|
Chen L, Okuda T, Lu XY, Chan HK. Amorphous powders for inhalation drug delivery. Adv Drug Deliv Rev 2016; 100:102-15. [PMID: 26780404 DOI: 10.1016/j.addr.2016.01.002] [Citation(s) in RCA: 125] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Revised: 12/23/2015] [Accepted: 01/02/2016] [Indexed: 11/25/2022]
Abstract
For inhalation drug delivery, amorphous powder formulations offer the benefits of increased bioavailability for poorly soluble drugs, improved biochemical stability for biologics, and expanded options of using various drugs and their combinations. However, amorphous formulations usually have poor physicochemical stability. This review focuses on inhalable amorphous powders, including the production methods, the active pharmaceutical ingredients and the excipients with a highlight on stabilization of the particles.
Collapse
|
67
|
Durham PG, Young EF, Braunstein MS, Welch JT, Hickey AJ. A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals. Int J Pharm 2016; 514:384-391. [PMID: 27130363 DOI: 10.1016/j.ijpharm.2016.04.063] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 04/24/2016] [Accepted: 04/25/2016] [Indexed: 11/18/2022]
Abstract
Combining the advantage of higher efficacy due to local pulmonary administration of pyrazinoic acid (POA) and potent effect of pyrazinoic acid ester (PAE) delivered as an aerosol would aid in tuberculosis therapy. A combination spray dried dry powder, composed of POA, PAE (n-propyl POA), maltodextrin and leucine, was prepared for aerosol delivery to animals. Solid-state characteristics of morphology (scanning electron microscopy) crystallinity (X-ray powder diffraction), thermal properties (thermogravimetric analysis and differential scanning calorimetry) and moisture content (Karl Fisher) were evaluated. Particle size distributions, by volume (laser diffraction) for the dispersed powder and by mass (inertial impaction) were determined. Efficient delivery of the powder to a nose only animal exposure chamber employed a novel rotating brush/micro-fan apparatus. Spherical, crystalline particles were prepared. The volume median diameter, ∼1.5μm, was smaller than the mass median aerodynamic diameter, ∼3.0μm, indicating modest aggregation. Drug content variations were observed across the particle size distribution and may be explained by PAE evaporative losses. Delivery to the nose-only exposure chamber indicated that boluses could be administered at approximately 3min intervals to avoid aerosol accumulation and effect uniform dose delivery with successive doses suitable for future pharmacokinetic and pharmacodynamic studies.
Collapse
Affiliation(s)
- P G Durham
- RTI International, Research Triangle Park, NC, USA.
| | - E F Young
- Department of Microbiology and Immunology, University of North Carolina-Chapel Hill Chapel Hill, NC, USA.
| | - M S Braunstein
- Department of Microbiology and Immunology, University of North Carolina-Chapel Hill Chapel Hill, NC, USA.
| | - J T Welch
- Department of Chemistry, University at Albany-SUNY, Albany, NY, USA.
| | - A J Hickey
- RTI International, Research Triangle Park, NC, USA.
| |
Collapse
|
68
|
Bandeira E, Lopes-Pacheco M, Chiaramoni N, Ferreira D, Fernandez-Ruocco MJ, Prieto MJ, Maron-Gutierrez T, Perrotta RM, de Castro-Faria-Neto HC, Rocco PRM, Alonso SDV, Morales MM. Association with Amino Acids Does Not Enhance Efficacy of Polymerized Liposomes As a System for Lung Gene Delivery. Front Physiol 2016; 7:151. [PMID: 27199766 PMCID: PMC4844622 DOI: 10.3389/fphys.2016.00151] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 04/08/2016] [Indexed: 11/13/2022] Open
Affiliation(s)
- Elga Bandeira
- Laboratory of Cellular and Molecular Physiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
- Laboratory of Pulmonary Investigation, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
| | - Miquéias Lopes-Pacheco
- Laboratory of Cellular and Molecular Physiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
- Laboratory of Pulmonary Investigation, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
| | - Nadia Chiaramoni
- Laboratory of Biomembranes, Department of Science and Technology, National University of QuilmesBuenos Aires, Argentina
| | - Débora Ferreira
- Laboratory of Cellular and Molecular Physiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
| | - Maria J. Fernandez-Ruocco
- Laboratory of Biomembranes, Department of Science and Technology, National University of QuilmesBuenos Aires, Argentina
| | - Maria J. Prieto
- Laboratory of Biomembranes, Department of Science and Technology, National University of QuilmesBuenos Aires, Argentina
| | | | - Ramiro M. Perrotta
- Laboratory of Biomembranes, Department of Science and Technology, National University of QuilmesBuenos Aires, Argentina
| | | | - Patricia R. M. Rocco
- Laboratory of Pulmonary Investigation, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
| | - Silvia del Valle Alonso
- Laboratory of Biomembranes, Department of Science and Technology, National University of QuilmesBuenos Aires, Argentina
| | - Marcelo M. Morales
- Laboratory of Cellular and Molecular Physiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de JaneiroRio de Janeiro, Brazil
- *Correspondence: Marcelo M. Morales
| |
Collapse
|
69
|
Haque S, Whittaker MR, McIntosh MP, Pouton CW, Kaminskas LM. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 12:1703-24. [PMID: 27033834 DOI: 10.1016/j.nano.2016.03.002] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 02/22/2016] [Accepted: 03/02/2016] [Indexed: 10/22/2022]
Abstract
The inhaled delivery of nanomedicines can provide a novel, non-invasive therapeutic strategy for the more localised treatment of lung-resident diseases and potentially also enable the systemic delivery of therapeutics that are otherwise administered via injection alone. However, the clinical translation of inhalable nanomedicine is being hampered by our lack of understanding about their disposition and clearance from the lungs. This review provides a comprehensive overview of the biodegradable nanomaterials that are currently being explored as inhalable drug delivery systems and our current understanding of their disposition within, and clearance from the lungs. The safety of biodegradable nanomaterials in the lungs is discussed and latest updates are provided on the impact of inflammation on the pulmonary pharmacokinetics of inhaled nanomaterials. Overall, the review provides an in-depth and critical assessment of the lung clearance mechanisms for inhaled biodegradable nanomedicines and highlights the opportunities and challenges for their translation into the clinic.
Collapse
Affiliation(s)
- Shadabul Haque
- Drug Delivery Disposition and Dynamics Group, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Michael R Whittaker
- Drug Delivery Disposition and Dynamics Group, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Michelle P McIntosh
- Drug Delivery Disposition and Dynamics Group, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Colin W Pouton
- Drug Delivery Disposition and Dynamics Group, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Lisa M Kaminskas
- Drug Delivery Disposition and Dynamics Group, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
| |
Collapse
|
70
|
Cipolla D, Blanchard J, Gonda I. Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics 2016; 8:pharmaceutics8010006. [PMID: 26938551 PMCID: PMC4810082 DOI: 10.3390/pharmaceutics8010006] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Revised: 02/22/2016] [Accepted: 02/23/2016] [Indexed: 12/03/2022] Open
Abstract
Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowarfare agents including Francisella tularensis, Yersinia pestis and Coxiella burnetii (which cause pneumonic tularemia, plague and Q fever, respectively). Delivery of an antibiotic formulation via the inhalation route has the potential to provide high concentrations at the site of infection with reduced systemic exposure to limit side effects. A liposomal formulation may improve tolerability, increase compliance by reducing the dosing frequency, and enhance penetration of biofilms and treatment of intracellular infections. Two liposomal ciprofloxacin formulations (Lipoquin® and Pulmaquin®) that are in development by Aradigm Corporation are described here.
Collapse
|
71
|
Potential of the isolated lung technique for the examination of sildenafil absorption from lung-delivered poly(lactide- co -glycolide) microparticles. J Control Release 2016; 226:15-20. [DOI: 10.1016/j.jconrel.2016.01.057] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 01/29/2016] [Accepted: 01/31/2016] [Indexed: 12/11/2022]
|
72
|
Sun L, Wan K, Hu X, Zhang Y, Yan Z, Feng J, Zhang J. Functional nanoemulsion-hybrid lipid nanocarriers enhance the bioavailability and anti-cancer activity of lipophilic diferuloylmethane. NANOTECHNOLOGY 2016; 27:085102. [PMID: 26808001 DOI: 10.1088/0957-4484/27/8/085102] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The purpose of this study was to assess the enhanced physicochemical characteristics, in vitro release behavior, anti-lung cancer activity, gastrointestinal absorption, in vivo bioavailability and bioequivalence of functional nanoemulsion-hybrid lipid nanocarriers containing diferuloylmethane (DNHLNs). The DNHLNs were first fabricated by loading water-in-oil nanoemulsions into hybrid lipid nanosystems using nanoemulsion-thin film-sonication dispersion technologies. The in situ absorption and in vitro and in vivo kinetic features of DNHLNs were measured using an in situ unidirectional perfusion method, a dynamic dialysis method and a plasma concentration-time profile-based method, respectively. The cytotoxic effects of DNHLNs in lung adenocarcinoma A549 cells were examined using MTT colorimetric analysis. The absorptive constants and permeabilities of DNHLNs in four gastrointestinal sections increased by 1.43-3.23 times and by 3.10-7.76 times that of diferuloylmethane (DIF), respectively. The relative bioavailability of DNHLNs to free DIF was 855.02%. DNHLNs inhibited cancer cell growth in a time- and dose-dependent manner. DNHLNs markedly improved the absorption and bioavailability of DIF after oral administration. DNHLNs had stronger inhibitory effects on the viability of A549 cells than that of free DIF. DNHLNs might be potentially promising nanocarriers for DIF delivery via the oral route to address unmet clinical needs.
Collapse
|
73
|
Singh MK, Shweta H, Khan MF, Sen S. New insight into probe-location dependent polarity and hydration at lipid/water interfaces: comparison between gel- and fluid-phases of lipid bilayers. Phys Chem Chem Phys 2016; 18:24185-97. [DOI: 10.1039/c6cp01201a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Location dependent polarity and hydration probed by a new series of 4-aminophthalimide-based fluorescent molecules (4AP-Cn;n= 2–10, 12) show different behaviour at gel- and fluid-phase lipid/water interfaces.
Collapse
Affiliation(s)
- Moirangthem Kiran Singh
- Spectroscopy Laboratory
- School of Physical Sciences
- Jawaharlal Nehru University
- New Delhi 110067
- India
| | - Him Shweta
- Spectroscopy Laboratory
- School of Physical Sciences
- Jawaharlal Nehru University
- New Delhi 110067
- India
| | - Mohammad Firoz Khan
- Spectroscopy Laboratory
- School of Physical Sciences
- Jawaharlal Nehru University
- New Delhi 110067
- India
| | - Sobhan Sen
- Spectroscopy Laboratory
- School of Physical Sciences
- Jawaharlal Nehru University
- New Delhi 110067
- India
| |
Collapse
|
74
|
Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 12:143-61. [DOI: 10.1016/j.nano.2015.09.004] [Citation(s) in RCA: 388] [Impact Index Per Article: 48.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 09/08/2015] [Accepted: 09/10/2015] [Indexed: 12/25/2022]
|
75
|
Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. Int J Pharm 2015; 497:199-209. [PMID: 26656946 DOI: 10.1016/j.ijpharm.2015.11.050] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Revised: 11/26/2015] [Accepted: 11/27/2015] [Indexed: 11/20/2022]
Abstract
Systemic administration of antitubercular drugs can be complicated by off-target toxicity to cells and tissues that are not infected by Mycobacterium tuberculosis . Delivery of antitubercular drugs via nanoparticles directly to the infected cells has the potential to maximize efficacy and minimize toxicity. The present work demonstrates the potential of solid lipid nanoparticles (SLN) as a delivery platform for rifabutin (RFB). Two different RFB-containing SLN formulations were produced using glyceryl dibehenate or glyceryl tristearate as lipid components. Full characterization was performed in terms of particle size, encapsulation and loading efficiency, morphology by transmission electron microscopy (TEM) and differential scanning calorimetry (DSC) studies. Physical stability was evaluated when formulations were stored at 5 ± 3°C and in the freeze-dried form. Formulations were stable throughout lyophilization without significant variations on physicochemical properties and RFB losses. The SLN showed to be able to endure harsh temperature conditions as demonstrated by dynamic light scattering (DLS). Release studies revealed that RFB was almost completely released from SLN. In vitro studies with THP1 cells differentiated in macrophages showing a nanoparticle uptake of 46 ± 3% and 26 ± 9% for glyceryl dibehenate and glyceryl tristearate SLN, respectively. Cell viability studies using relevant lung cell lines (A549 and Calu-3) revealed low cytotoxicity for the SLN, suggesting these could be new potential vehicles for pulmonary delivery of antitubercular drugs.
Collapse
|
76
|
Kakhi Z, Frisch B, Bourel-Bonnet L, Hemmerlé J, Pons F, Heurtault B. Airway administration of a highly versatile peptide-based liposomal construct for local and distant antitumoral vaccination. Int J Pharm 2015; 496:1047-56. [PMID: 26602294 DOI: 10.1016/j.ijpharm.2015.11.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 11/13/2015] [Accepted: 11/14/2015] [Indexed: 01/28/2023]
Abstract
With the discovery of tumor-associated antigens such as ErbB2, vaccination is considered as a promising strategy to prevent the development of cancer or treat the existing disease. Among routes of immunization, the respiratory route provides the opportunity to develop non-invasive approach for vaccine delivery. In the current study, this administration route was used in order to investigate the potency of a highly versatile di-epitopic liposomal construct to exhibit local or distant antitumoral efficiency after prophylactic or therapeutic vaccination in mice. Well-characterized liposomes, containing the ErbB2 (p63-71) TCD8(+) and HA (p307-319) TCD4(+) peptide epitopes and the Pam2CAG adjuvant, were formulated and administered into the airway of naïve BALB/c mice. The nanoparticle vaccine candidate induced local and specific systemic immune response, as measured by immune cell infiltration and chemokine and cytokine production in BALF or lung tissue, and by spleen T-cell activation ex vivo, respectively. This potent immune response resulted in an efficient antitumor activity against both lung and solid s.c. tumors. Interestingly, the antitumor efficacy was observed after both prophylactic and therapeutic vaccinations, which are the most judicious ones to fight cancer. Our data showed an undeniable interest of liposomal peptide-based vaccines in antitumor vaccination by the respiratory route, opening new perspectives for cancer treatment.
Collapse
Affiliation(s)
- Zahra Kakhi
- Equipe de Biovectorologie, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Benoît Frisch
- Equipe de Biovectorologie, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | - Line Bourel-Bonnet
- Equipe de Biovectorologie, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France
| | | | - Françoise Pons
- Equipe de Biovectorologie, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France.
| | - Béatrice Heurtault
- Equipe de Biovectorologie, Laboratoire de Conception et Application de Molécules Bioactives, UMR 7199CNRS/Université de Strasbourg, Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch Cedex, France.
| |
Collapse
|
77
|
Tagami T, Kubota M, Ozeki T. Effective Remote Loading of Doxorubicin into DPPC/Poloxamer 188 Hybrid Liposome to Retain Thermosensitive Property and the Assessment of Carrier-Based Acute Cytotoxicity for Pulmonary Administration. J Pharm Sci 2015; 104:3824-3832. [DOI: 10.1002/jps.24593] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 06/19/2015] [Accepted: 06/29/2015] [Indexed: 11/12/2022]
|
78
|
Cipolla D, Wu H, Gonda I, Chan HK. Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. J Aerosol Med Pulm Drug Deliv 2015; 28:411-22. [PMID: 26469306 PMCID: PMC4685509 DOI: 10.1089/jamp.2015.1241] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background: Previously we showed that the release properties of a liposomal ciprofloxacin (CFI) formulation could be attenuated by incorporation of drug nanocrystals within the vesicles. Rather than forming these drug nanocrystals during drug loading, they were created post manufacture simply by freezing and thawing the formulation. The addition of surfactant to CFI, either polysorbate 20 or Brij 30, provided an additional means to modify the release profile or incorporate an immediate-release or ‘burst’ component as well. The goal of this study was to develop a CFI formulation that retained its nanocrystalline morphology and attenuated release profile after delivery as an inhaled aerosol. Methods: Preparations of 12.5 mg/mL CFI containing 90 mg/mL sucrose and 0.1% polysorbate 20 were formulated between pH 4.6 to 5.9, stored frozen, and thawed prior to use. These thawed formulations, before and after mesh nebulization, and after subsequent refrigerated storage for up to 6 weeks, were characterized in terms of liposome structure by cryogenic transmission electron microscopy (cryo-TEM) imaging, vesicle size by dynamic light scattering, pH, drug encapsulation by centrifugation-filtration, and in vitro release (IVR) performance. Results: Within the narrower pH range of 4.9 to 5.3, these 12.5 mg/mL liposomal ciprofloxacin formulations containing 90 mg/mL sucrose and 0.1% polysorbate 20 retained their physicochemical stability for an additional 3 months refrigerated storage post freeze-thaw, were robust to mesh nebulization maintaining their vesicular form containing nanocrystalline drug and an associated slower release profile, and formed respirable aerosols with a mass median aerodynamic diameter (MMAD) of ∼3.9 μm and a geometric standard deviation (GSD) of ∼1.5. Conclusions: This study demonstrates that an attenuated release liposomal ciprofloxacin formulation can be created through incorporation of drug nanocrystals in response to freeze-thaw, and the formulation retains its physicochemical properties after aerosolization by mesh nebulizer.
Collapse
Affiliation(s)
- David Cipolla
- 1 Department of Pharmacuetical Sciences, Aradigm Inc. , Hayward, California.,2 Faculty of Pharmacy, University of Sydney , Sydney, New South Wales, Australia
| | - Huiying Wu
- 1 Department of Pharmacuetical Sciences, Aradigm Inc. , Hayward, California
| | - Igor Gonda
- 1 Department of Pharmacuetical Sciences, Aradigm Inc. , Hayward, California
| | - Hak-Kim Chan
- 2 Faculty of Pharmacy, University of Sydney , Sydney, New South Wales, Australia
| |
Collapse
|
79
|
Ladavière C, Gref R. Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems. Nanomedicine (Lond) 2015; 10:3033-3055. [PMID: 26420270 DOI: 10.2217/nnm.15.128] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Intracellular pathogenic bacteria can lead to some of the most life-threatening infections. By evolving a number of ingenious mechanisms, these bacteria have the ability to invade, colonize and survive in the host cells in active or latent forms over prolonged period of time. A variety of nanoparticulate systems have been developed to optimize the delivery of antibiotics. Main advantages of nanoparticulate systems as compared with free drugs are an efficient drug encapsulation, protection from inactivation, targeting infection sites and the possibility to deliver drugs by overcoming cellular barriers. Nevertheless, despite the great progresses in treating intracellular infections using nanoparticulate carriers, some challenges still remain, such as targeting cellular subcompartments with bacteria and delivering synergistic drug combinations. Engineered nanoparticles should allow controlling drug release both inside cells and within the extracellular space before reaching the target cells.
Collapse
Affiliation(s)
- Catherine Ladavière
- UMR CNRS 5223, IMP, Université Lyon 1, INSA de Lyon, 69100 Villeurbanne, France
| | - Ruxandra Gref
- Institute of Molecular Sciences, UMR CNRS 8214, Université Paris-Saclay, 91400 Orsay, France
| |
Collapse
|
80
|
Naseri N, Valizadeh H, Zakeri-Milani P. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull 2015; 5:305-13. [PMID: 26504751 DOI: 10.15171/apb.2015.043] [Citation(s) in RCA: 499] [Impact Index Per Article: 55.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 06/15/2015] [Accepted: 06/19/2015] [Indexed: 11/09/2022] Open
Abstract
Lipid nanoparticles (LNPs) have attracted special interest during last few decades. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are two major types of Lipid-based nanoparticles. SLNs were developed to overcome the limitations of other colloidal carriers, such as emulsions, liposomes and polymeric nanoparticles because they have advantages like good release profile and targeted drug delivery with excellent physical stability. In the next generation of the lipid nanoparticle, NLCs are modified SLNs which improve the stability and capacity loading. Three structural models of NLCs have been proposed. These LNPs have potential applications in drug delivery field, research, cosmetics, clinical medicine, etc. This article focuses on features, structure and innovation of LNPs and presents a wide discussion about preparation methods, advantages, disadvantages and applications of LNPs by focusing on SLNs and NLCs.
Collapse
Affiliation(s)
- Neda Naseri
- Student Research Committee and Faculty of Advanced Medical Sciences, Department of Medical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Hadi Valizadeh
- Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Parvin Zakeri-Milani
- Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
81
|
Moreno-Sastre M, Pastor M, Salomon CJ, Esquisabel A, Pedraz JL. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J Antimicrob Chemother 2015. [DOI: 10.1093/jac/dkv192] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
82
|
Di Gioia S, Trapani A, Castellani S, Carbone A, Belgiovine G, Craparo EF, Puglisi G, Cavallaro G, Trapani G, Conese M. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier. Pulm Pharmacol Ther 2015; 34:8-24. [PMID: 26192479 DOI: 10.1016/j.pupt.2015.07.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 06/04/2015] [Accepted: 07/06/2015] [Indexed: 12/21/2022]
Abstract
Gene therapy, i.e. the delivery and expression of therapeutic genes, holds great promise for congenital and acquired respiratory diseases. Non-viral vectors are less toxic and immunogenic than viral vectors, although they are characterized by lower efficiency. However, they have to overcome many barriers, including inflammatory and immune mediators and cells. The respiratory and airway epithelial cells, the main target of these vectors, are coated with a layer of mucus, which hampers the effective reaching of gene therapy vectors carrying either plasmid DNA or small interfering RNA. This barrier is thicker in many lung diseases, such as cystic fibrosis. This review summarizes the most important advancements in the field of non-viral vectors that have been achieved with the use of nanoparticulate (NP) systems, composed either of polymers or lipids, in the lung gene delivery. In particular, different strategies of targeting of respiratory and airway lung cells will be described. Then, we will focus on the two approaches that attempt to overcome the mucus barrier: coating of the nanoparticulate system with poly(ethylene glycol) and treatment with mucolytics. Our conclusions are: 1) Ligand and physical targeting can direct therapeutic gene expression in specific cell types in the respiratory tract; 2) Mucopenetrating NPs are endowed with promising features to be useful in treating respiratory diseases and should be now advanced in pre-clinical trials. Finally, we discuss the development of such polymer- and lipid-based NPs in the context of in vitro and in vivo disease models, such as lung cancer, as well as in clinical trials.
Collapse
Affiliation(s)
- Sante Di Gioia
- Department of Medical and Surgical Sciences, University of Foggia, Viale L. Pinto 1, 71122 Foggia, Italy
| | - Adriana Trapani
- Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via Orabona, 4, 70125 Bari, Italy
| | - Stefano Castellani
- Department of Medical and Surgical Sciences, University of Foggia, Viale L. Pinto 1, 71122 Foggia, Italy
| | - Annalucia Carbone
- Department of Medical and Surgical Sciences, University of Foggia, Viale L. Pinto 1, 71122 Foggia, Italy; Medical Genetics Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 12, 20122 Milan, Italy
| | - Giuliana Belgiovine
- Department of Medical and Surgical Sciences, University of Foggia, Viale L. Pinto 1, 71122 Foggia, Italy
| | - Emanuela Fabiola Craparo
- Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Laboratory of Biocompatible Polymers, University of Palermo, Via Archirafi 32, 90123 Palermo, Italy
| | - Giovanni Puglisi
- Dipartimento di Scienze del Farmaco, Università degli Studi di Catania, Viale A. Doria, 6, 95125 Catania, Italy
| | - Gennara Cavallaro
- Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), Laboratory of Biocompatible Polymers, University of Palermo, Via Archirafi 32, 90123 Palermo, Italy
| | - Giuseppe Trapani
- Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via Orabona, 4, 70125 Bari, Italy
| | - Massimo Conese
- Department of Medical and Surgical Sciences, University of Foggia, Viale L. Pinto 1, 71122 Foggia, Italy.
| |
Collapse
|
83
|
Formulation and nebulization of fluticasone propionate-loaded lipid nanocarriers. Int J Pharm 2015; 493:224-32. [PMID: 26183331 DOI: 10.1016/j.ijpharm.2015.07.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2015] [Revised: 07/01/2015] [Accepted: 07/02/2015] [Indexed: 11/21/2022]
Abstract
Inhaled fluticasone propionate (FP) is often prescribed as a first-line therapy for the effective management of pulmonary diseases such as asthma. As nanocarriers offer many advantages over other drug delivery systems, this study investigated the suitability of lipid nanocapsules (LNCs) as a carrier for fluticasone propionate, examining the drug-related factors that should be considered in the formulation design and the behaviour of LNCs with different compositions and properties suspended within aerosol droplets under the relatively hostile conditions of nebulization. By adjusting the formulation conditions, particularly the nanocarrier composition, FP was efficiently encapsulated within the LNCs with a yield of up to 97%, and a concentration comparable to commercially available preparations was achieved. Moreover, testing the solubility of the drug in oil and water and determining the oil/water partition coefficient proved to be useful when assessing the encapsulation of the FP in the LNC formulation. Nebulization did not cause the FP to leak from the formulation, and no phase separation was observed after nebulization. LNCs with a diameter of 100 nm containing a smaller amount of surfactant and a larger amount of oil provided a better FP-loading capacity and better stability during nebulization than 30 or 60 nm LNCs.
Collapse
|
84
|
Feng TS, Tian HY, Xu CN, Lin L, Lam MHW, Liang HJ, Chen XS. Doxorubicin-loaded PLGA microparticles with internal pores for long-acting release in pulmonary tumor inhalation treatment. CHINESE JOURNAL OF POLYMER SCIENCE 2015. [DOI: 10.1007/s10118-015-1642-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
85
|
Zhou QT, Leung SSY, Tang P, Parumasivam T, Loh ZH, Chan HK. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev 2015; 85:83-99. [PMID: 25451137 DOI: 10.1016/j.addr.2014.10.022] [Citation(s) in RCA: 161] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 10/15/2014] [Accepted: 10/18/2014] [Indexed: 11/16/2022]
Abstract
Respiratory infections represent a major global health problem. They are often treated by parenteral administrations of antimicrobials. Unfortunately, systemic therapies of high-dose antimicrobials can lead to severe adverse effects and this calls for a need to develop inhaled formulations that enable targeted drug delivery to the airways with minimal systemic drug exposure. Recent technological advances facilitate the development of inhaled anti-microbial therapies. The newer mesh nebulisers have achieved minimal drug residue, higher aerosolisation efficiencies and rapid administration compared to traditional jet nebulisers. Novel particle engineering and intelligent device design also make dry powder inhalers appealing for the delivery of high-dose antibiotics. In view of the fact that no new antibiotic entities against multi-drug resistant bacteria have come close to commercialisation, advanced formulation strategies are in high demand for combating respiratory 'super bugs'.
Collapse
Affiliation(s)
- Qi Tony Zhou
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
| | - Sharon Shui Yee Leung
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
| | - Patricia Tang
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
| | - Thaigarajan Parumasivam
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
| | - Zhi Hui Loh
- GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
| | - Hak-Kim Chan
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia.
| |
Collapse
|
86
|
Hidalgo A, Cruz A, Pérez-Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur J Pharm Biopharm 2015; 95:117-27. [PMID: 25709061 DOI: 10.1016/j.ejpb.2015.02.014] [Citation(s) in RCA: 123] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2014] [Revised: 01/28/2015] [Accepted: 02/06/2015] [Indexed: 11/29/2022]
Abstract
To consider the lung as a target for drug delivery and to optimise strategies directed at the pulmonary route, it is essential to consider the role of pulmonary surfactant, a thin lipid-protein film lining the respiratory surface of mammalian lungs. Membrane-based surfactant multilayers are essential for reducing the surface tension at the respiratory air-liquid interface to minimise the work of breathing. Different components of surfactant are also responsible for facilitating the removal of potentially pathological entities such as microorganisms, allergens or environmental pollutants and particles. Upon inhalation, drugs or nanoparticles first contact the surfactant layer, and these interactions critically affect their lifetime and fate in the airways. This review summarises the current knowledge on the possible role and effects of the pulmonary surfactant system in drug delivery strategies. It also summarises the evidence that suggests that pulmonary surfactant is far from being an insuperable barrier and could be used as an efficient shuttle for delivering hydrophobic and hydrophilic compounds deep into the lung and the organism.
Collapse
Affiliation(s)
- Alberto Hidalgo
- Dept. of Biochemistry, Fac. of Biology, and Research Institute Hospital 12 Octubre, Universidad Complutense, Madrid, Spain
| | - Antonio Cruz
- Dept. of Biochemistry, Fac. of Biology, and Research Institute Hospital 12 Octubre, Universidad Complutense, Madrid, Spain
| | - Jesús Pérez-Gil
- Dept. of Biochemistry, Fac. of Biology, and Research Institute Hospital 12 Octubre, Universidad Complutense, Madrid, Spain.
| |
Collapse
|
87
|
Witting M, Obst K, Friess W, Hedtrich S. Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers. Biotechnol Adv 2015; 33:1355-69. [PMID: 25687276 DOI: 10.1016/j.biotechadv.2015.01.010] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Revised: 01/27/2015] [Accepted: 01/27/2015] [Indexed: 11/19/2022]
Abstract
Proteins and peptides are increasingly important therapeutics for the treatment of severe and complex diseases like cancer or autoimmune diseases due to their high specificity and potency. Their unique structure and labile physicochemical properties, however, require special attention in the production and formulation process as well as during administration. Aside from conventional systemic injections, the topical application of proteins and peptides is an appealing alternative due to its non-invasive nature and thus high acceptance by patients. For this approach, soft matter nanocarriers are interesting delivery systems which offer beneficial properties such as high biocompatibility, easiness of modifications, as well as targeted drug delivery and release. This review aims to highlight and discuss technological developments in the field of soft matter nanocarriers for the delivery of proteins and peptides via the skin, the eye, the nose, and the lung, and to provide insights in advantages, limitations, and practicability of recent advances.
Collapse
Affiliation(s)
- Madeleine Witting
- Department of Pharmaceutical Sciences, Ludwig-Maximilians-Universität, Munich, Germany
| | - Katja Obst
- Institute for Pharmaceutical Sciences, Freie Universität Berlin, Germany
| | - Wolfgang Friess
- Department of Pharmaceutical Sciences, Ludwig-Maximilians-Universität, Munich, Germany
| | - Sarah Hedtrich
- Institute for Pharmaceutical Sciences, Freie Universität Berlin, Germany.
| |
Collapse
|